AstraZeneca (AZN) shares gain on acquisition news

AstraZeneca (LON: AZN) expands its presence in rare disease development with a further acquisition, sending its shares higher.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

AstraZeneca (LSE: AZN) shares put on 3% in early trading Wednesday, after news of a new acquisition. The AstraZeneca share price is now up 18% over the past two years, and up 74% over five.

Via its Alexion subsidiary, the pharmaceuticals giant has agreed to buy out rare disease specialist Caelum Biosciences in a deal worth up to $500m. Alexion already held a minority interest in Caelum, with a full buyout option. It will now pay an initial $150m to take full control. Additional payments will reach up to $350m, depending on hitting regulatory and commercial milestones.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

AstraZeneca acquired Alexion itself only recently, with the deal completing in July 2021. The move marked a milestone in the company’s expansion into rare disease research.

Caelum has developed CAEL-101, a monoclonal antibody for the treatment of light chain (AL) amyloidosis. According to AstraZeneca’s description, “AL amyloidosis is a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys, causing significant organ damage and failure that may ultimately be fatal.”

Astrazeneca pipeline addition

The company reckons that around 20,000 people across the UK, US and parts of Europe currently suffer from advanced stages of the disease. That’s a relatively small number in drug sales terms, so CAEL-101 is not going to be a big blockbuster. But it’s a significant number of patients, and the drug adds to the growing number of new treatments coming through AstraZeneca’s pipeline.

Phase III trials of the CAEL-101 antibody treatment will now take place. They will involve a total of 380 newly diagnosed AL amyloidosis patients, with enrolment currently underway.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic…

And with so many great companies still trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool is here to help: our UK Chief Investment Officer and his analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global lock-down…

You see, here at The Motley Fool we don’t believe “over-trading” is the right path to financial freedom in retirement; instead, we advocate buying and holding (for AT LEAST three to five years) 15 or more quality companies, with shareholder-focused management teams at the helm.

That’s why we’re sharing the names of all five of these companies in a special investing report that you can download today for FREE. If you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio, and that you can consider building a position in all five right away.

Click here to claim your free copy of this special investing report now!

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Stack of British pound coins falling on list of share prices
Investing Articles

3 distressed stocks with huge potential that I’m considering for my portfolio!

These three distressed stocks have performed badly in 2022, but that doesn't mean they won't recover. Here's why I'm considering…

Read more »

Luxury inside of NIO car
Investing Articles

Here’s why I’ve just bought NIO shares!

I've recently bought NIO shares, despite the stock being down nearly 80% over the past year. Here's why!

Read more »

Mature people enjoying time together during road trip
Investing Articles

Is now the time to buy Tesla shares?

Tesla's share price has fallen in 2022 and so has its valuation. Edward Sheldon looks at whether this is a…

Read more »

A graph made of neon tubes in a room
Investing Articles

Are Woodbois shares worth me buying at 4.7p?

Jon Smith considers the recent surge in price for Woodbois shares, and wonders if the move lower last week represents…

Read more »

Shot of a senior man drinking coffee and looking thoughtfully out of a window
Investing Articles

How I’d generate a passive income for life with just £20 a week

Dividend shares can be an excellent way to earn a passive income for life. Our writer discusses a plan to…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Hargreaves Lansdown investors are buying these cheap FTSE 100 shares. Should I?

Paul Summers takes a closer look at two cheap FTSE 100 stocks that were proving very popular with investors last…

Read more »

A retired couple review their investing portfolio
Investing Articles

Investing in dividend stocks: 5 shares with BIG yields to buy!

I think investing in stocks is a great idea following recent market volatility. I can pick up some of the…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

I’d buy these top UK shares with £1,000

Jon Smith explains how he'd split his £1,000 cash and also notes the top UK shares he wants to invest…

Read more »